Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis

NCT01483144 is registered in ClinicalTrials.gov with Cancer Prevention Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01483144
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01483144 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of the Safety and Efficacy of Eflornithine Combined With Sulindac Compared to Eflornithine, Sulindac as Single Agents in Patients With Familial Adenomatous Polyposis
Lead sponsor
Cancer Prevention Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2013
Completion date
March 31, 2019
Enrollment
171 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

familial adenomatous polyposis